Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection-Lessons for Functional HBV Cure?
Jennifer Audsley, Anchalee Avihingsanon, Margaret Littlejohn, Scott Bowden, Gail Matthews, Christopher K Fairley, Sharon R Lewin, Joe Sasadeusz
Journal of Acquired Immune Deficiency Syndromes | LIPPINCOTT WILLIAMS & WILKINS | Published : 2020
BACKGROUND: Tenofovir disoproxil fumarate (TDF) is effective in suppressing HIV and hepatitis B virus (HBV) replication in HIV-HBV coinfection although HBV DNA can persist in some individuals on TDF-containing antiretroviral therapy (ART). We initiated a prospective longitudinal study to determine durability of HBV virological control and clinical outcomes after prolonged TDF-based ART in HIV-HBV coinfection. METHODS: Ninety-two HIV-HBV coinfected participants on, or about to commence, TDF-containing ART from Australia (n = 41) and Thailand (n = 52) were enrolled. Participants were followed 6-monthly for 2 years, then annually to 5 years. Laboratory and clinical assessments and a serum sampl..View full abstract
Supported by Gilead Sciences.